Defective autophagy and autophagy activators in myasthenia gravis: a rare entity and unusual scenario

References

• Dresser L, Wlodarski R, Rezania K, et al. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235. doi: 10.3390/jcm10112235
   PubMed Web of Science ®Google Scholar
• Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020;11:212. doi: 10.3389/fimmu.2020.00212
   PubMed Web of Science ®Google Scholar
• Ciafaloni E. Myasthenia gravis and congenital myasthenic syndromes. Contin Lifelong Learn Neurol. 2019;25(6):1767–1784. doi: 10.1212/CON.0000000000000800
   Google Scholar
• Iijima S. Clinical and pathophysiologic relevance of autoantibodies in neonatal myasthenia gravis. Pediatr Neonatol. 2021;62(6):581–590. doi: 10.1016/j.pedneo.2021.05.020
   PubMed Web of Science ®Google Scholar
• Luchanok V, Kaminski HJ. 90Natural history of myasthenia gravis. In Myasthenia gravis and myasthenic disorders. Oxford University Press; 2012. doi: 10.1093/med/9780199738670.003.0004
   Google Scholar
• Nguyen-Cao TM, Gelinas D, Griffin R, et al. Myasthenia gravis: historical achievements and the “golden age” of clinical trials. J Neurol Sci. 2019;406:116428. doi: 10.1016/j.jns.2019.116428
   PubMed Web of Science ®Google Scholar
• Catalin J, Silviana J, Claudia B. Clinical presentation of myasthenia gravis. London, (UK): Thymus Rezaei N InTechOpen; 2020. pp. 91–99.
   Google Scholar
• Alanazy MH. Clinical features and outcomes of patients with myasthenia gravis. Neurosciences (Riyadh). 2019;24(3):176–184. doi: 10.17712/nsj.2019.3.20190011
   PubMed Web of Science ®Google Scholar
• Yildiz Celik S, Durmus H, Yilmaz V, et al. Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome. Acta Neurol Belg. 2020;120(1):133–140. doi: 10.1007/s13760-019-01252-x
   PubMed Web of Science ®Google Scholar
• Evoli A, Iorio R. Controversies in ocular myasthenia gravis. Front Neurol. 2020;11:605902. doi: 10.3389/fneur.2020.605902
   PubMed Web of Science ®Google Scholar
• Hendricks TM, Bhatti MT, Hodge DO, et al. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol. 2019;205:99–105. doi: 10.1016/j.ajo.2019.04.017
   PubMed Web of Science ®Google Scholar
• Wong SH, Eggenberger E, Cornblath W, et al. Preliminary findings of a dedicated ocular myasthenia gravis rating scale: the OMGRate. Neuroophthalmology. 2020;44(3):148–156. doi: 10.1080/01658107.2019.1660686
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang F, Long Z, et al. Mortality of myasthenia gravis: a national population-based study in China. Ann Clin Transl Neurol. 2023;10(7):1095–1105. doi: 10.1002/acn3.51792
   PubMed Web of Science ®Google Scholar
• Katz NK, Barohn RJ. The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis. Neuropharmacology. 2021;182:108303. doi: 10.1016/j.neuropharm.2020.108303
   PubMed Web of Science ®Google Scholar
• Bubuioc A-M, Kudebayeva A, Turuspekova S, et al. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7. doi: 10.25122/jml-2020-0145
   PubMedGoogle Scholar
• Salari N, Fatahi B, Bartina Y, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021;19(1):1–23. doi: 10.1186/s12967-021-03185-7
   PubMed Web of Science ®Google Scholar
• Peragallo JH, Bitrian E, Kupersmith MJ, et al. Relationship between age, gender, and race in patients presenting with myasthenia gravis with only ocular manifestations. J Neuro-Ophthalmol. 2016;36(1):29–32. doi: 10.1097/WNO.0000000000000276
   PubMed Web of Science ®Google Scholar
• Tanovska N, Novotni G, Sazdova-Burneska S, et al. Myasthenia gravis and associated diseases. Open Access Maced J Med Sci. 2018;6(3):472. doi: 10.3889/oamjms.2018.110
   PubMedGoogle Scholar
• Fichtner ML, Jiang R, Bourke A, et al. Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol. 2020;11:776. doi: 10.3389/fimmu.2020.00776
   PubMed Web of Science ®Google Scholar
• Borges LS, Richman DP. Muscle-specific kinase myasthenia gravis. Front Immunol. 2020;11:707. doi: 10.3389/fimmu.2020.00707
   PubMed Web of Science ®Google Scholar
• Ingelfinger F, Krishnarajah S, Kramer M, et al. Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. Acta Neuropathol. 2021;141(6):901–915. doi: 10.1007/s00401-021-02299-y
   PubMed Web of Science ®Google Scholar
• Rahman MM, Islam MR, Dhar PS. Myasthenia gravis in current status: epidemiology, types, etiology, pathophysiology, symptoms, diagnostic tests, prevention, treatment, and complications–correspondence. Int J Surg. 2023;109(2):178–180. doi: 10.1097/JS9.0000000000000164
   PubMed Web of Science ®Google Scholar
• Hayashi M. Childhood myasthenia gravis in Japan: pathophysiology and treatment options. Clin Exp Neuroimmunol. 2023;14(4):185–194. doi: 10.1111/cen3.12762
   Google Scholar
• Qian K, Xu J-X, Deng Y, et al. Signaling pathways of genetic variants and miRnas in the pathogenesis of myasthenia gravis. Gland Surg. 2020;9(6):1933. doi: 10.21037/gs-20-39
   PubMed Web of Science ®Google Scholar
• Yan M, Fu Y, Rao H, et al. Expression and clinical significance of miR-146a and tumor necrosis factor receptor-associated factor 6 (TRAF6) in myasthenia gravis patient serum. Biomed Res Int. 2021;2021:1–6. doi: 10.1155/2021/5573469
   PubMed Web of Science ®Google Scholar
• Álvarez‐Velasco R, Gutiérrez‐Gutiérrez G, Trujillo JC, et al. Clinical characteristics and outcomes of thymoma‐associated myasthenia gravis. Eur J Neurol. 2021;28(6):2083–2091. doi: 10.1111/ene.14820
   PubMed Web of Science ®Google Scholar
• Rodolico C, Bonanno C, Toscano A, et al. MuSK-associated myasthenia gravis: clinical features and management. Front Neurol. 2020;11:660. doi: 10.3389/fneur.2020.00660
   PubMed Web of Science ®Google Scholar
• Muhammed L, Baheerathan A, Cao M, et al. MuSK antibody–associated myasthenia gravis with SARS-CoV-2 infection: a case report. Ann Intern Med. 2021;174(6):872–873. doi: 10.7326/L20-1298
   PubMed Web of Science ®Google Scholar
• Deymeer F. Myasthenia gravis: MuSK MG, late-onset MG and ocular MG. Acta Myol. 2020;39(4):345. doi: 10.36185/2532-1900-038
   PubMedGoogle Scholar
• Huijbers MG, Vergoossen DL, Fillié-Grijpma YE, et al. MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity. Neurol Neuroinflammation. 2019;6(3). doi: 10.1212/NXI.0000000000000547
   Google Scholar
• Wu Y, Luo J, Garden OA. Immunoregulatory cells in myasthenia gravis. Front Neurol. 2020;11:593431. doi: 10.3389/fneur.2020.593431
   PubMed Web of Science ®Google Scholar
• Stathopoulos P, Kumar A, Vander HJ, et al. Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis. Ann N Y Acad Sci. 2018;1412(1):154–165. doi: 10.1111/nyas.13535
   PubMed Web of Science ®Google Scholar
• Yi JS, Guptill JT, Stathopoulos P, et al. B cells in the pathophysiology of myasthenia gravis. Muscle Nerve. 2018;57(2):172–184. doi: 10.1002/mus.25973
   PubMed Web of Science ®Google Scholar
• Çebi M, Durmus H, Aysal F, et al. CD4+ T cells of myasthenia gravis patients are characterized by increased IL-21, IL-4, and IL-17A productions and higher presence of PD-1 and ICOS. Front Immunol. 2020;11:809. doi: 10.3389/fimmu.2020.00809
   PubMed Web of Science ®Google Scholar
• Guo F, Wang C, Wang S, et al. Alteration in gene expression profile of thymomas with or without myasthenia gravis linked with the nuclear factor‐kappaB/autoimmune regulator pathway to myasthenia gravis pathogenesis. Thorac Cancer. 2019;10(3):564–570. doi: 10.1111/1759-7714.12980
   PubMed Web of Science ®Google Scholar
• Yu S, Yan J, Fang Y, et al. Effect of thymectomy on the frequencies of peripheral regulatory B and T lymphocytes in patients with myasthenia gravis-a pilot study. Int J Neurosci. 2023;2023:1–10. doi:10.1080/00207454.2023.2254922
   Google Scholar
• Villegas JA, Bayer AC, Ider K, et al. Il-23/Th17 cell pathway: a promising target to alleviate thymic inflammation maintenance in myasthenia gravis. J Autoimmun. 2019;98:59–73. doi: 10.1016/j.jaut.2018.11.005
   PubMed Web of Science ®Google Scholar
• Huang X, Zhu J, Liu T, et al. Increased expression of CD95 in CD4(+) effector memory T cells promotes Th17 response in patients with myasthenia gravis. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol. 2022;17(3–4):437–452. doi: 10.1007/s11481-021-10030-7
   PubMed Web of Science ®Google Scholar
• Chen P, Tang X. Gut microbiota as regulators of Th17/Treg balance in patients with myasthenia gravis. Front Immunol. 2021;12:803101. doi: 10.3389/fimmu.2021.803101
   PubMed Web of Science ®Google Scholar
• Al-Kuraishy HM, Jabir MS, Al-Gareeb AI, et al. The beneficial role of autophagy in multiple sclerosis: yes or No? Autophagy. 2023;20(2):259–274. doi: 10.1080/15548627.2023.2259281
   PubMed Web of Science ®Google Scholar
• Tang J, Ye Z, Liu Y, et al. Autophagy-deficiency in bone marrow mononuclear cells from patients with myasthenia gravis: a possible mechanism of pathogenesis. Int J Neurosci. 2021;131(3):239–253. doi: 10.1080/00207454.2020.1738429
   PubMed Web of Science ®Google Scholar
• Ichimiya T, Yamakawa T, Hirano T, et al. Autophagy and Autophagy-Related Diseases: A Review. Int J Mol Sci. 2020;21(23). doi: 10.3390/ijms21238974
   PubMed Web of Science ®Google Scholar
• Lei Y, Klionsky DJ. The emerging roles of autophagy in human diseases. Biomedicines. 2021;9(11). doi: 10.3390/biomedicines9111651
   Web of Science ®Google Scholar
• Klionsky DJ, Petroni G, Amaravadi RK, et al. Autophagy in major human diseases. EMBO J. 2021;40(19):e108863. doi: 10.15252/embj.2021108863
   PubMed Web of Science ®Google Scholar
• Gatica D, Lahiri V, Klionsky DJ. Cargo recognition and degradation by selective autophagy. Nat Cell Biol. 2018;20(3):233–242. doi: 10.1038/s41556-018-0037-z
   PubMed Web of Science ®Google Scholar
• Roach PJ. AMPK -> ULK1 -> autophagy. Mol Cell Biol. 2011;31(15):3082–3084. doi: 10.1128/MCB.05565-11
   PubMed Web of Science ®Google Scholar
• Liu H-T, Pan S-S. Late exercise preconditioning promotes autophagy against exhaustive exercise-induced myocardial injury through the activation of the AMPK-mTOR-ULK1 pathway. Biomed Res Int. 2019;2019:5697380. doi: 10.1155/2019/5697380
   PubMed Web of Science ®Google Scholar
• Wang S, Wuniqiemu T, Tang W, et al. Luteolin inhibits autophagy in allergic asthma by activating PI3K/Akt/mTOR signaling and inhibiting beclin-1-PI3KC3 complex. Int Immunopharmacol. 2021;94:107460. doi: 10.1016/j.intimp.2021.107460
   PubMed Web of Science ®Google Scholar
• Yu L, Chen Y, Tooze SA. Autophagy pathway: cellular and molecular mechanisms. Autophagy. 2018;14(2):207–215. doi: 10.1080/15548627.2017.1378838
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhou J, Xiao P, et al. PtdIns4P restriction by hydrolase SAC1 decides specific fusion of autophagosomes with lysosomes. Autophagy. 2021;17(8):1907–1917. doi: 10.1080/15548627.2020.1796321
   PubMed Web of Science ®Google Scholar
• Yang Z, Goronzy JJ, Weyand CM. Autophagy in autoimmune disease. J Mol Med (Berl). 2015;93(7):707–717. doi: 10.1007/s00109-015-1297-8
   PubMed Web of Science ®Google Scholar
• Yin H, Wu H, Chen Y, et al. The Therapeutic and Pathogenic Role of Autophagy in Autoimmune Diseases. Front Immunol. 2018;9:1512. doi: 10.3389/fimmu.2018.01512
   PubMed Web of Science ®Google Scholar
• Martinez-Pena Y, Valenzuela I, Akaaboune M. The Metabolic Stability of the Nicotinic Acetylcholine Receptor at the Neuromuscular Junction. Cells. 2021;10(2):358. doi: 10.3390/cells10020358
   PubMed Web of Science ®Google Scholar
• Carnio S, LoVerso F, Baraibar MA, et al. Autophagy impairment in muscle induces neuromuscular junction degeneration and precocious aging. Cell Rep. 2014;8(5):1509–1521. doi: 10.1016/j.celrep.2014.07.061
   PubMed Web of Science ®Google Scholar
• Baraldo M, Geremia A, Pirazzini M, et al. Skeletal muscle mTORC1 regulates neuromuscular junction stability. J Cachexia Sarcopenia Muscle. 2020;11(1):208–225. doi: 10.1002/jcsm.12496
   PubMed Web of Science ®Google Scholar
• Ke L, Li Q, Song J, et al. The mitochondrial biogenesis signaling pathway is a potential therapeutic target for myasthenia gravis via energy metabolism (review). Exp Ther Med. 2021;22(1):702. doi: 10.3892/etm.2021.10134
   PubMed Web of Science ®Google Scholar
• Song J, Lei X, Jiao W, et al. Effect of Qiangji Jianli decoction on mitochondrial respiratory chain activity and expression of mitochondrial fusion and fission proteins in myasthenia gravis rats. Sci Rep. 2018;8(1):8623. doi: 10.1038/s41598-018-26918-z
   PubMedGoogle Scholar
• Kordas G, Lagoumintzis G, Sideris S, et al. Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients. PLoS One. 2014;9(9):e108327. doi: 10.1371/journal.pone.0108327
   PubMed Web of Science ®Google Scholar
• Wohlgemuth SE, Calvani R, Marzetti E. The interplay between autophagy and mitochondrial dysfunction in oxidative stress-induced cardiac aging and pathology. J Mol Cell Cardiol. 2014;71:62–70. doi: 10.1016/j.yjmcc.2014.03.007
   PubMed Web of Science ®Google Scholar
• Wu JJ, Quijano C, Chen E, et al. Mitochondrial dysfunction and oxidative stress mediate the physiological impairment induced by the disruption of autophagy. Aging. 2009;1(4):425–437. doi: 10.18632/aging.100038
   PubMedGoogle Scholar
• Gorgey AS, Witt O, O’Brien L, et al. Mitochondrial health and muscle plasticity after spinal cord injury. Eur J Appl Physiol. 2019;119(2):315–331. doi: 10.1007/s00421-018-4039-0
   PubMed Web of Science ®Google Scholar
• Vercauteren K, Gleyzer N, Scarpulla RC. PGC-1-related coactivator complexes with HCF-1 and NRF-2beta in mediating NRF-2(GABP)-dependent respiratory gene expression. J Biol Chem. 2008;283(18):12102–12111. doi: 10.1074/jbc.M710150200
   PubMed Web of Science ®Google Scholar
• Taherzadeh-Fard E, Saft C, Akkad DA, et al. PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease. Mol Neurodegener. 2011;6(1):32. doi: 10.1186/1750-1326-6-32
   PubMedGoogle Scholar
• Chauhan M, Punga T, Punga AR. Muscle-specific regulation of the mTOR signaling pathway in MuSK antibody seropositive (MuSK+) experimental autoimmune myasthenia gravis (EAMG). Neurosci Res. 2013;77(1–2):102–109. doi: 10.1016/j.neures.2013.07.008
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen S, Wang Y, et al. Dexamethasone improves thymoma-associated myasthenia gravis via the AKT-mTOR pathway. Naunyn Schmiedebergs Arch Pharmacol. 2023;397(2):817–828. doi: 10.1007/s00210-023-02641-z
   PubMed Web of Science ®Google Scholar
• Troncoso R, Paredes F, Parra V, et al. Dexamethasone-induced autophagy mediates muscle atrophy through mitochondrial clearance. Cell Cycle. 2014;13(14):2281–2295. doi: 10.4161/cc.29272
   PubMed Web of Science ®Google Scholar
• Zhang J, Jin H, Xu Y, et al. Rapamycin modulate Treg/Th17 balance via regulating metabolic pathways: a study in mice. Transplant Proc. 2019;51(6):2136–2140. doi: 10.1016/j.transproceed.2019.04.067
   PubMed Web of Science ®Google Scholar
• Jing F, Yang F, Cui F, et al. Rapamycin alleviates inflammation and muscle weakness, while altering the Treg/Th17 balance in a rat model of myasthenia gravis. Biosci Rep. 2017;37(4). doi: 10.1042/BSR20170767
   Google Scholar
• Al-Bari MAA, Xu P. Molecular regulation of autophagy machinery by mTOR-dependent and -independent pathways. Ann N Y Acad Sci. 2020;1467(1):3–20. doi: 10.1111/nyas.14305
   PubMed Web of Science ®Google Scholar
• Bronietzki AW, Schuster M, Schmitz I. Autophagy in T-cell development, activation and differentiation. Immunol Cell Biol. 2015;93(1):25–34. doi: 10.1038/icb.2014.81
   PubMed Web of Science ®Google Scholar
• Guptill JT, Soni M, Meriggioli MN. Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis. Neurother J Am Soc Exp Neurother. 2016;13(1):118–131. doi: 10.1007/s13311-015-0398-y
   Google Scholar
• Pacholczyk R, Ignatowicz H, Kraj P, et al. Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells. Immunity. 2006;25(2):249–259. doi: 10.1016/j.immuni.2006.05.016
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang H, Chi L, et al. The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis. Immunol Lett. 2009;122(1):52–57. doi: 10.1016/j.imlet.2008.11.015
   PubMed Web of Science ®Google Scholar
• Alahgholi-Hajibehzad M, Kasapoglu P, Jafari R, et al. The role of T regulatory cells in immunopathogenesis of myasthenia gravis: implications for therapeutics. Expert Rev Clin Immunol. 2015;11(7):859–870. doi: 10.1586/1744666X.2015.1047345
   PubMed Web of Science ®Google Scholar
• Wang N, Yuan J, Karim MR, et al. Effects of mitophagy on regulatory T cell function in patients with myasthenia gravis. Front Neurol. 2020;11:238. doi: 10.3389/fneur.2020.00238
   PubMed Web of Science ®Google Scholar
• Aricha R, Reuveni D, Fuchs S, et al. Suppression of experimental autoimmune myasthenia gravis by autologous T regulatory cells. J Autoimmun. 2016;67:57–64. doi: 10.1016/j.jaut.2015.09.005
   PubMed Web of Science ®Google Scholar
• Rowin J, Thiruppathi M, Arhebamen E, et al. Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 2012;46(3):449–453. doi: 10.1002/mus.23488
   PubMed Web of Science ®Google Scholar
• Sandoval H, Kodali S, Wang J. Regulation of B cell fate, survival, and function by mitochondria and autophagy. Mitochondrion. 2018;41:58–65. doi: 10.1016/j.mito.2017.11.005
   PubMed Web of Science ®Google Scholar
• Martinez-Martin N, Maldonado P, Gasparrini F, et al. A switch from canonical to noncanonical autophagy shapes B cell responses. Science. 2017;355(6325):641–647. doi: 10.1126/science.aal3908
   PubMed Web of Science ®Google Scholar
• Pengo N, Scolari M, Oliva L, et al. Plasma cells require autophagy for sustainable immunoglobulin production. Nat Immunol. 2013;14(3):298–305. doi: 10.1038/ni.2524
   PubMed Web of Science ®Google Scholar
• Conway KL, Kuballa P, Khor B, et al. ATG5 regulates plasma cell differentiation. Autophagy. 2013;9(4):528–537. doi: 10.4161/auto.23484
   PubMed Web of Science ®Google Scholar
• Arnold J, Murera D, Arbogast F, et al. Autophagy is dispensable for B-cell development but essential for humoral autoimmune responses. Cell Death Differ. 2016;23(5):853–864. doi: 10.1038/cdd.2015.149
   PubMed Web of Science ®Google Scholar
• Aichinger M, Wu C, Nedjic J, et al. Macroautophagy substrates are loaded onto MHC class II of medullary thymic epithelial cells for central tolerance. J Exp Med. 2013;210(2):287–300. doi: 10.1084/jem.20122149
   PubMed Web of Science ®Google Scholar
• Nedjic J, Aichinger M, Emmerich J, et al. Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. Nature. 2008;455(7211):396–400. doi: 10.1038/nature07208
   PubMed Web of Science ®Google Scholar
• Postoak JL, Song W, Yang G, et al. Thymic epithelial cells require lipid kinase Vps34 for CD4 but not CD8 T cell selection. J Exp Med. 2022;219(10):e20212554. doi: 10.1084/jem.20212554
   PubMed Web of Science ®Google Scholar
• Rodrigues PM, Sousa LG, Perrod C, et al. LAMP2 regulates autophagy in the thymic epithelium and thymic stroma-dependent CD4 T cell development. Autophagy. 2023;19(2):426–439. doi: 10.1080/15548627.2022.2074105
   PubMed Web of Science ®Google Scholar
• Gómez-Oca R, Cowling BS, Laporte J. Common pathogenic mechanisms in centronuclear and myotubular myopathies and latest treatment advances. Int J Mol Sci. 2021;22(21):11377. doi: 10.3390/ijms222111377
   PubMed Web of Science ®Google Scholar
• Schuster C, Gerold KD, Schober K, et al. The autoimmunity-associated gene CLEC16A modulates thymic epithelial cell autophagy and alters T cell selection. Immunity. 2015;42(5):942–952. doi: 10.1016/j.immuni.2015.04.011
   PubMed Web of Science ®Google Scholar
• Wang N, Shen N, Vyse TJ, et al. Selective IgA deficiency in autoimmune diseases. Mol Med. 2011;17(11–12):1383–1396. doi: 10.2119/molmed.2011.00195
   PubMed Web of Science ®Google Scholar
• Wei J, Long L, Yang K, et al. Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis. Nat Immunol. 2016;17(3):277–285. doi: 10.1038/ni.3365
   PubMed Web of Science ®Google Scholar
• Kabat AM, Harrison OJ, Riffelmacher T, et al. The autophagy gene Atg16l1 differentially regulates Treg and TH2 cells to control intestinal inflammation. Elife. 2016;5:e12444. doi: 10.7554/eLife.12444
   PubMed Web of Science ®Google Scholar
• Mocholi E, Dowling SD, Botbol Y, et al. Autophagy is a tolerance-avoidance mechanism that modulates TCR-mediated signaling and cell metabolism to prevent induction of T cell anergy. Cell Rep. 2018;24(5):1136–1150. doi: 10.1016/j.celrep.2018.06.065
   PubMed Web of Science ®Google Scholar
• Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, et al. Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: a hidden treasure. J Diabetes. 2022;14(12):806–814. doi: 10.1111/1753-0407.13334
   PubMed Web of Science ®Google Scholar
• Al-Kuraishy HM, Al-Gareeb AI, Waheed HJ, et al. Differential effect of metformin and/or glyburide on apelin serum levels in patients with type 2 diabetes mellitus: concepts and clinical practice. J Adv Pharm Technol Res. 2018;9(3):80–86. doi: 10.4103/japtr.JAPTR_273_18
   PubMedGoogle Scholar
• Al-Kuraishy H, Hamada M, Al-Samerraie A. Effects of metformin on omentin levels in a newly diagnosed type II diabetes mellitus: randomized, placebo controlled study. Mustansiriya Med J. 2016;Vol(1):49–55. doi: 10.4103/2070-1128.248840
   Google Scholar
• Al-Kuraishy HM, Al-Gareeb AI, Saad HM, et al. Long-term use of metformin and Alzheimer’s disease: beneficial or detrimental effects. Inflammopharmacology. 2023;31(3):1107–1115. doi: 10.1007/s10787-023-01163-7
   PubMed Web of Science ®Google Scholar
• Alnaaim SA, Al-Kuraishy HM, Al-Gareeb AI, et al. New insights on the potential anti-epileptic effect of metformin: mechanistic pathway. J Cell Mol Med. 2023;27(24):3953–3965. doi: 10.1111/jcmm.17965
   PubMed Web of Science ®Google Scholar
• Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, et al. Metformin role in Parkinson’s disease: a double-sword effect. Mol Cell Biochem 2023. doi: 10.1007/s11010-023-04771-7
   Google Scholar
• Ali N, Alhamdan N, Al-Kuraishy H, et al. Irisin/PGC-1α/FNDC5 pathway in Parkinson’s disease: truth under the throes. Naunyn Schmiedebergs Arch Pharmacol. 2023;1–11. doi: 10.1007/s00210-023-02726-9
   Web of Science ®Google Scholar
• Lu G, Wu Z, Shang J, et al. The effects of metformin on autophagy. Biomed Pharmacother. 2021;137:111286. doi: 10.1016/j.biopha.2021.111286
   PubMed Web of Science ®Google Scholar
• Bharath LP, Agrawal M, McCambridge G, et al. Metformin enhances autophagy and normalizes mitochondrial function to alleviate aging-associated inflammation. Cell Metab. 2020;32(1):44–55.e6. doi: 10.1016/j.cmet.2020.04.015
   PubMed Web of Science ®Google Scholar
• Cui Y, Chang L, Wang C, et al. Metformin attenuates autoimmune disease of the neuromotor system in animal models of myasthenia gravis. Int Immunopharmacol. 2019;75:105822. doi: 10.1016/j.intimp.2019.105822
   PubMed Web of Science ®Google Scholar
• Hao Y, Zhao W, Chang L, et al. Metformin inhibits the pathogenic functions of AChR-specific B and Th17 cells by targeting miR-146a. Immunol Lett. 2022;250:29–40. doi: 10.1016/j.imlet.2022.09.002
   PubMed Web of Science ®Google Scholar
• Ren H, Shao Y, Wu C, et al. Metformin alleviates oxidative stress and enhances autophagy in diabetic kidney disease via AMPK/SIRT1-FoxO1 pathway. Mol Cell Endocrinol. 2020;500:110628. doi: 10.1016/j.mce.2019.110628
   PubMed Web of Science ®Google Scholar
• Jiao W, Hu F, Li J, et al. Qiangji Jianli Decoction promotes mitochondrial biogenesis in skeletal muscle of myasthenia gravis rats via AMPK/PGC-1α signaling pathway. Biomed Pharmacother. 2020;129:110482. doi: 10.1016/j.biopha.2020.110482
   PubMed Web of Science ®Google Scholar
• Li Q, Jia S, Xu L, et al. Metformin-induced autophagy and irisin improves INS-1 cell function and survival in high-glucose environment via AMPK/SIRT1/PGC-1α signal pathway. Food Sci Nutr. 2019;7(5):1695–1703. doi: 10.1002/fsn3.1006
   PubMed Web of Science ®Google Scholar
• Ge J, Huang Y, Zhang Y, et al. Metformin inhibits propofol-induced apoptosis of mouse hippocampal neurons HT-22 through downregulating cav-1. Drug Des Devel Ther 2020;14:1561–1569. 10.2147/DDDT.S229520.
   PubMed Web of Science ®Google Scholar
• Damri O, Shemesh N, Agam G. Is there justification to treat neurodegenerative disorders by repurposing drugs? The case of Alzheimer’s disease, lithium, and autophagy. Int J Mol Sci. 2020;22(1). doi: 10.3390/ijms22010189
   PubMed Web of Science ®Google Scholar
• Taskaeva IS, Bgatova NP, Solovieva AO. Autophagy in hepatocellular carcinoma-29 after single or combined administration of lithium carbonate and rapamycin. Cell Tissue Biol. 2019;13(5):353–359. doi: 10.1134/S1990519X19050079
   Google Scholar
• Alevizos B, Gatzonis S, Anagnostara C. Myasthenia gravis disclosed by lithium carbonate. J Neuropsychiatry Clin Neurosci. 2006;18(3):427–429. doi: 10.1176/jnp.2006.18.3.427
   PubMed Web of Science ®Google Scholar
• Afonso TM, Ferreira F, Cativo C, et al. Psychopharmacology in myasthenia gravis patients: a case study. Eur Psychiatry. 2023;66(Suppl 1):S274.
   Google Scholar
• Sheikh S, Alvi U, Soliven B, et al. Drugs that induce or cause deterioration of myasthenia gravis: an update. J Clin Med. 2021;10(7). doi: 10.3390/jcm10071537
   Web of Science ®Google Scholar
• Al-Kuraishy H. Erectile dysfunction and statins: the assorted view of preponderance. Asian Pac J Reprod. 2020;9(2):55–63. doi: 10.4103/2305-0500.281074
   Google Scholar
• Al-Kuraishy HM, Al-Gareeb AI, Saad HM, et al. The potential therapeutic effect of statins in multiple sclerosis: beneficial or detrimental effects. Inflammopharmacology. 2023;31(4):1671–1682. doi: 10.1007/s10787-023-01240-x
   PubMed Web of Science ®Google Scholar
• Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, et al. Pros and cons for statins use and risk of Parkinson’s disease: an updated perspective. Pharmacol Res Perspect. 2023;11(2):e01063. doi: 10.1002/prp2.1063
   PubMed Web of Science ®Google Scholar
• Alsubaie N, Al-Kuraishy HM, Al-Gareeb AI, et al. Statins use in alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci. 2022;12(10):1290. doi: 10.3390/brainsci12101290
   PubMed Web of Science ®Google Scholar
• Liu L, Dai W-Z, Zhu X-C, et al. A review of autophagy mechanism of statins in the potential therapy of Alzheimer’s disease. J Integr Neurosci. 2022;21(2):46. doi: 10.31083/j.jin2102046
   PubMed Web of Science ®Google Scholar
• Gale J, Danesh-Meyer HV. Statins can induce myasthenia gravis. J Clin Neurosci Off J Neurosurg Soc Australas. 2014;21(2):195–197. doi: 10.1016/j.jocn.2013.11.009
   PubMed Web of Science ®Google Scholar
• Oh SJ, Dhall R, Young A, et al. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008;38(3):1101–1107. doi: 10.1002/mus.21074
   PubMed Web of Science ®Google Scholar
• Gras‐Champel V, Batteux B, Masmoudi K, et al. Statin-induced myasthenia: a disproportionality analysis of the WHO’s VigiBase pharmacovigilance database. Muscle And Nerve. 2019;382–386. doi: 10.1002/mus.26637 60 4
   PubMed Web of Science ®Google Scholar
• Zhang P, Liu R-T, Du T, et al. Exosomes derived from statin-modified bone marrow dendritic cells increase thymus-derived natural regulatory T cells in experimental autoimmune myasthenia gravis. J Neuroinflammation. 2019;16(1):202. doi: 10.1186/s12974-019-1587-0
   PubMed Web of Science ®Google Scholar